Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

No abstract is available for this paper.

• Publication year

  2001

• Venue

  AIDS (London)

• Publication date

  2001-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002030-200105040-00005PMID 11399957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine

  2000cited by this paper
• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

  2000cited by this paper
• Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

  1999cited by this paper
• Fat distribution and metabolic changes in patients with HIV infection.

  1999cited by this paper
• Lipodystrophy in patients naive to HIV protease inhibitors.

  1999cited by this paper
• Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy.

  1999cited by this paper
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

  1999cited by this paper
• Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

  1999cited by this paper
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

  1999cited by this paper
• Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

  1999cited by this paper
• "Buffalo hump" in men with HIV-1 infection.

  1998cited by this paper
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Visceral abdominal-fat accumulation associated with use of indinavir.

  1998cited by this paper
• Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

  1994cited by this paper
• Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.

  1991cited by this paper
• FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

  year unknowncited by this paper

• Assessment of regional body composition, physical function and sarcopenia among peruvian women aging with HIV: A cross-sectional study

  2023cites this paper
• Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors.

  2020cites this paper
• Markers of adiposity in HIV/AIDS patients: Agreement between waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index

  2018cites this paper
• Lipodystrophy diagnosis in people living with HIV/AIDS: prediction and validation of sex-specific anthropometric models

  2018cites this paper
• Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the South West Regional Hospitals of Cameroon: a cross-sectional study

  2018cites this paper
• Lipodystrophy syndrome in HIV-infected patients – a cohort study in Lower Silesia, Poland

  2017influential citation
• SURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014.

  2017cites this paper
• Metabolic and Skeletal Complications of HIV Infection

  2017cites this paper
• Pattern of dyslipidaemia in human immunodeficiency virus infected patients- a study from rural tertiary care hospital in central India

  2016cites this paper
• HIV Infection and Diabetes

  2016cites this paper
• Treatment of Dyslipidemia in HIV

  2015cites this paper
• Heterogeneity in Nutritional and Lipid Profiles in Children and Adolescents with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy

  2015cites this paper
• Dyslipidemia in HIV-Infected Patients

  2015cites this paper
• Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

  2014cites this paper
• Wpływ zespołu lipodystrofii na subkliniczną miażdżycę tętnic szyjnych u pacjentów zakażonych HIV

  2014cites this paper
• A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz

  2014cites this paper
• An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes

  2014cites this paper
• Human immunodeficiency virus (HIV) associated lipodystrophy: The prevalence, severity and phenotypes in patients on highly active anti-retroviral therapy (HAART) in Kenya

  2013cites this paper
• Impact of age on markers of HIV-1 disease.

  2013cites this paper
• HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

  2013cites this paper
• Investigation of lipodystrophy syndrome in a multicentre prospective cohort of HIV-infected children and adolescents living in Europe

  2013cites this paper
• Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence

  2013cites this paper
• Factors associated with the development of HIV associated lipodystrophy in patients on long-term HAART

  2012cites this paper
• The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care

  2012cites this paper
• Nutrition and the HIV-associated lipodystrophy syndrome

  2012cites this paper
• Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04

  2011cites this paper
• Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada

  2011cites this paper
• The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy *

  2011cites this paper
• HIV and HAART-Associated Dyslipidemia

  2011cites this paper
• Antiretroviral therapy and its impact on lipid metabolic parameters

  2011cites this paper
• Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine

  2011cites this paper
• Fat Distribution in Men With HIV Infection From the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM)

  2011cites this paper
• The pilot study of DXA assessment in chinese HIV-infected men with clinical lipodystrophy.

  2011cites this paper
• Combination antiretroviral therapy -associated lipodystrophy : insights into pathogenesis and treatment

  2011cites this paper
• Tesamorelin

  2011cites this paper
• HIV Infection and Diabetes

  2010cites this paper
• Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy--an observational study.

  2010cites this paper
• Treatment of dyslipidemia in HIV-infected patients

  2010cites this paper
• Prevalence and Impact of Body Physical Changes in HIV Patients Treated with Highly Active Antiretroviral Therapy: Results from a Study on Patient and Physician Perceptions

  2010cites this paper
• Syndromes of Extreme Insulin Resistance

  2010cites this paper
• Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

  2010cites this paper
• UvA-DARE ( Digital Academic Repository ) Autonomic nervous control of white adipose tissue : studies on the role of the brain in body fat distribution

  2009cites this paper
• Trends in the European HIV/AIDS epidemic: a perspective from Italy

  2009cites this paper
• In vivo-Analyse der hepatischen mitochondrialen Funktion HIV-infizierter Patienten durch den 13 C- Methionin-Atemtest

  2009cites this paper
• Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy.

  2009cites this paper
• CHAPTER 43 – Special Patient Populations: HIV Patients

  2009cites this paper
• PPARs in Viral Disease

  2009influential citation
• A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.

  2009cites this paper
• Strategies to limit the metabolic complications of treatment for HIV infection

  2009cites this paper
• How sweet it is? Susceptibility to diabetes mellitus in HIV-1 treatment

  2009cites this paper
• Metabolic abnormalities associated with HIV infection and antiretroviral therapy

  2009cites this paper
• Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic

  2009cites this paper
• Lipid Profile Abnormalities in People Living with HIV and AIDS

  2008cites this paper
• Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection

  2008cites this paper
• Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

  2008cites this paper
• Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients

  2008cites this paper
• Drug-induced paraparotid fat deposition in patients with HIV: case reports.

  2008cites this paper
• Mitochondrial Oxidative Phosphorylation Protein Levels in Peripheral Blood Mononuclear Cells Correlate with Levels in Subcutaneous Adipose Tissue within Samples Differing by HIV and Lipoatrophy Status

  2008cites this paper
• Pá P ulas umbilicadas diseminadas asociadas a infección P or ViH- sida

  2008cites this paper
• Lopinavir/ritonavir monotherapy as maintenance treatment in HIV‐infected individuals with virological suppression: results from a pilot study in Brazil

  2008cites this paper
• Monoterapia con lopinavir potenciado con ritonavir como estrategia de simplificación del tratamiento antirretroviral en la práctica clínica

  2008cites this paper
• [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].

  2008cites this paper
• [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].

  2008cites this paper
• The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

  2008cites this paper
• Lipids in Health and Disease

  2008cites this paper
• Monoterapia con lopinavir/ritonavir como estrategia de simplificación en el tratamiento del virus de la inmunodeficiencia humana Tipo 1

  2008cites this paper
• Mitochondrial Toxicity of Indinavir, Stavudine and Zidovudine Involves Multiple Cellular Targets in white and brown adipocytes

  2007cites this paper
• Les métalloprotéases matricielles 2 et 9 et la différenciation des cellules progénitrices du tissu adipeux humain

  2007cites this paper
• Brief Report: Stavudine but not Didanosine as Part of HAART Contributes to Peripheral Lipoatrophy: A Substudy from the Antiretroviral Regimen Evaluation Study (ARES)

  2007cites this paper
• Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strategy

  2007cites this paper
• Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen

  2007cites this paper
• Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s)

  2007cites this paper
• Strategies in the treatment of HIV-1-associated adipose redistribution syndromes

  2007cites this paper
• Oral glucose loading for detection of mitochondrial toxicity during HAART in HIV-infected patients.

  2007cites this paper
• Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.

  2007cites this paper
• Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

  2006cites this paper
• Lipids in Health and Disease

  2006cites this paper
• Appearance-Related Side Effects of HIV-1 Treatment

  2006cites this paper
• Sleutel tot succes

  2006cites this paper
• The influence of APOBEC3G and deoxythymidylate kinase genetic diversity on HIV-1 hypermutation and response to treatment

  2006cites this paper
• Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study

  2006cites this paper
• Adverse Effects of Antiretroviral Drugs on HIV-1-Infected and -Uninfected Human Monocyte-Derived Macrophages

  2006cites this paper
• Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy.

  2006cites this paper
• Sympathetic nervous system function in HIV-associated adipose redistribution syndrome

  2006cites this paper
• Switching strategies to improve lipid profile and morphologic changes.

  2006cites this paper
• High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochondrial Respiration in Mice

  2006cites this paper
• Metabolic and skeletal complications of HIV infection: the price of success.

  2006cites this paper
• Fat Distribution in Women With HIV Infection

  2006cites this paper
• Toxic metabolic syndrome associated with HAART

  2006cites this paper
• Metabolic complications of HIV therapy.

  2006cites this paper
• THE INFLUENCE OF APOBEC 3 G AND DEOXYTHYMIDYLATE KINASE GENETIC DIVERSITY ON HIV-1 HYPERMUTATION AND RESPONSE TO TREATMENT

  2006cites this paper
• Mitochondrial Toxicity and Lipodystrophy

  2006cites this paper
• Is oxygen a key factor in the lipodystrophy phenotype?

  2006cites this paper
• Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study)

  2005cites this paper
• Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors.

  2005cites this paper
• Nucleoside Analogue-Sparing Strategy for the Treatment of Chronic HIV Infection: Potential Interest and Clinical Experience

  2005cites this paper
• Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.

  2005influential citation
• In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

  2005cites this paper
• Sequencing antiretroviral drugs for long-lasting suppression of HIV replication.

  2005cites this paper
• Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

  2005cites this paper